Business Wire

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Share

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures. The ILBM is integrated into LivaNova’s next-generation CPB platform, the Essenz™ Perfusion System, which allows perfusionists to access and manage reliable blood parameters directly from the system’s cockpit, without the need for additional monitors or holders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830793488/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Essenz In-Line Blood Monitor shown with the Essenz Perfusion System (Photo: Business Wire)

Existing blood gas analyzers only reflect a patient’s clinical condition at the exact moment a sample is drawn, which can quickly change and become irrelevant.1,2 With the Essenz ILBM, perfusionists receive in-line continuous monitoring of the patient’s parameters for the duration of a procedure. This allows for the delivery of a patient-tailored approach to perfusion rooted in data-driven decisions.

“Dynamic conditions can rapidly change a patient’s blood parameters during a cardiopulmonary bypass procedure,” said Marco Dolci, LivaNova President, Cardiopulmonary. “The Essenz In-Line Blood Monitor provides continuous monitoring throughout a patient’s procedure. Access to accurate, real-time measurements directly from the Essenz Perfusion System allows for quick decisions and tailored care strategies to serve the patient.”

Powered by the proven B-Capta™ sensing technology, the Essenz ILBM is the only in-line blood monitoring system that works within Clinical Laboratory Improvement Amendments (CLIA) guidelines and provides parameter values in line with hospital blood gas analyzers, even prior to alignment.3 To enable accurate monitoring, the ILBM provides measured values for oxygen saturation, hematocrit, partial pressure of oxygen and temperature, rather than calculated values for these parameters.

In addition, Essenz ILBM requires no calibration to set device measurements, allowing the perfusionist to save time during device set up, especially in emergency cases. Arterial and venous parameters are automatically transferred to the Essenz™ Patient Monitor, supporting data-driven decision making and the implementation of goal-directed perfusion (GDP), a therapy effective in reducing the risk of acute kidney injury.4 The latest heart-lung machine software, version 1.3, integrates the ILBM with the Essenz Perfusion System and was developed to continually enhance the user experience.

Based on 50 years of trusted partnership, the Essenz Perfusion System was designed and developed in collaboration with more than 300 customers worldwide. It consists of a next-generation heart-lung machine (HLM), a patient monitor and accurate sensing technology that now includes the ILBM. The Essenz Perfusion System is currently available in Europe, the U.S., Canada, Australia, Japan and the United Arab Emirates. Since its launch in February 2023, more than 1,000 patients worldwide have been supported with this system. Learn more about the entire Essenz Perfusion System on the LivaNova website.

View the Essenz Perfusion System brand video here.

*Note: The Essenz HLM is not available for sale in all geographies. Visit the LivaNova website for important safety information.

References

  1. Ottens J. et all. Improving Cardiopulmonary Bypass: Does Continuous Blood Gas Monitoring Have a Role to Play? - JECT. 2010;42:191–198
  2. Trowbridge CC et al., The Effects of Continuous Blood Gas Monitoring During Cardiopulmonary Bypass: A Prospective, Randomized Study-Part II, The Journal of Extracorporeal Technology, 2000
  3. Perfusion, 2022, Vol. 0(0) 1–7, Marloes van Hoeven, Eddy Overdevest, Joyce Curvers, Henri van Heugten: A comparison of continuous blood gas monitors during cardiopulmonary bypass LivaNova B-Capta, Terumo CDI 500, spectrum medical M4
  4. Goal-Directed Perfusion to reduce Acute Kidney Injury: A Randomized Trial Ranucci M. et al.
    J Thorac Cardiovasc Surg. 2018 Nov; 156(5): 1918-1927.e2.
    doi.org/10.1016/j.jtcvs.2018.04.045

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Essenz Perfusion System, Essenz HLM, the Essenz Patient Monitor and the Essenz ILBM. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
Director, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kenvue to Announce Third Quarter 2023 Results on October 26, 202322.9.2023 13:30:00 EEST | Press release

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its third quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at https://investors.kenvue.com. A replay will be available approximately two hours after the live event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary

OS Achieves 800-Puff Milestone with FEELM Max Technology22.9.2023 12:34:00 EEST | Press release

A significant mark in the vaping industry was set when OS Vape, a pioneering disposable product series from OS, showcased its dynamic range at the InterTabac from September 14th to 16th in Germany. Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels. Drawing upon this rich resource base, OS's foray into the disposable e-cigarette domain promises consumers enhanced puff counts, cost-efficiency, and unparalleled vapor consistency. As revealed by Future Marketing Insights, Europe's disposable market witnessed a substantial surge, accounting for a 32.3% revenue share in 2022. This robust growth underscores the escalating consumer preference for hassle-free, smokeless alternatives that eliminate the need for recharges or refills. The evolution of the disposable sector brings heightened convenience and a broader array of choices for consumers. Capitalizing on this trend, OS, through its innovative product series and leveraging it

Earnix Announces New London Office, Unveils New Tech and Launches Global Modelling Contest at Earnix Eˣcelerate Summit 202322.9.2023 11:00:00 EEST | Press release

Earnix, the global provider of intelligent, SaaS solutions for insurers and banks, celebrated its 12th annual Eˣcelerate Summit by announcing a new London office to collaborate with its growing customer base, unveiling Model Accelerator, and launching its first global modelling contest. Held September 20-21 in London, Earnix Eˣcelerate brought together hundreds of financial services business leaders to discuss insurance insights, perspectives, case studies and approaches impacting the evolution of the industry. “Earnix Eˣcelerate was a world-class event dedicated to discussing industry challenges and discovering the latest technology innovation to address them,” said Karun Arathil, senior analyst, Celent. “I found the forum engaging and interactive, and it was great to exchange ideas and gain perspective with industry leaders from around the world.” In other news, Earnix announced a new upgraded office presence in London, located in Devonshire Square. The space affords local employees

Europe’s Enterprises Look to Providers to Bridge the CX Gap22.9.2023 11:00:00 EEST | Press release

Enterprises throughout Europe are rapidly moving from in-house operations to external service providers to meet the growing demand for an enhanced contact center customer experience (CX), according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2023 ISG Provider Lens™ Customer Experience Services report for Europe finds that most executives in Europe and worldwide consider CX a top strategic priority and intend to “completely protect” CX from cost optimization programs. Providers are responding to this increased demand by delivering advanced, location-independent CX with high AI and automation content, the report says. “Over the past few years, the need for resilient and advanced digital CX has increased dramatically,” said Jill Stabler, partner, ISG Enterprise. “This has led to a corresponding surge of activities in this space.” Technology has played a crucial role in shaping the C

JTI: Combatting Illegal Trade and a Collective Approach to Sustainability Were the Focus at the Global Tobacco and Nicotine Forum in Seoul22.9.2023 10:00:00 EEST | Press release

The Global Tobacco and Nicotine Forum (GTNF) took place in Seoul, South Korea 19-21 September. “Change the Conversation. Change the Outcome.” was the theme of the conference which brought together hundreds of stakeholders from across the industry, including businesses, research consulting groups, scientists, public policy and regulatory experts and educators, among others, to discuss industry trends and challenges and share best practice thinking. Among those participating in the forum were Julian Cheung, Anti-Illicit Trade Operations Director of Asia-Pacific region, and Ana Krasojevic, Sustainability Strategy and Reporting Director, both from JTI. Anti-illicit trade: The time for action is now During her keynote address, Julian Cheung said that “Criminal groups involved in the illegal tobacco trade, siphon much-needed tax revenue from state budgets. They don’t comply with laws and regulations and, therefore, taxpayers, governments and legitimate businesses are all paying a hefty price

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom